Drug Information

Drug (ID: DG01726) and It's Reported Resistant Information

Name	Ruxolitinib/ZSTK474
Synonyms	Ruxolitinib/ZSTK474 Click to Show/Hide
Target	.	NOUNIPROTAC	[1]

Type(s) of Resistant Mechanism of This Drug

ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)			Click to Show/Hide
Key Molecule: Tyrosine-protein kinase JAK2 (JAK3)				[1]
Molecule Alteration	Missense mutation		p.V617F (c.1849G>T)	Molecule Info
Sensitive Disease	Solid tumour/cancer [ICD-11: 2A00-2F9Z]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	Ba/F3 cells	Colon	Homo sapiens (Human)	CVCL_0161
In Vivo Model	JAK2 mutant Ba/F3 tumour mouse model			Mus musculus
Experiment for Molecule Alteration	Western blotting analysis
Experiment for Drug Resistance	CellTiter-Glo assay; Colony assay

References

Ref 1	Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitorsJ Cell Mol Med. 2013 Nov;17(11):1397-409. doi: 10.1111/jcmm.12156. Epub 2013 Nov 19.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.